Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 16, 2023 - Issue
Submit an article Journal homepage
155
Views
1
CrossRef citations to date
0
Altmetric
CASE REPORT

Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report

Cuifen Zhang1 the First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of ChinaView further author information
,
Ke Wang1 the First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of ChinaView further author information
,
Hong Zhang1 the First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of ChinaView further author information
,
Jingjing Liu1 the First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of ChinaView further author information
,
Chuangjie Zheng1 the First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of ChinaView further author information
,
Jiahao Tao1 the First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of ChinaView further author information
,
Lizhu Lin2 Cancer Center, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of ChinaView further author information
&
Linzhu Zhai3 Cancer Center, Departments of Radiation Oncology, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People’s Republic of ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8507-7220View further author information
ORCID Icon show all
Pages 2429-2432 | Received 21 Jun 2023, Accepted 25 Aug 2023, Published online: 05 Sep 2023

References

  • Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937
  • Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, Phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6
  • De Ruysscher D, Ramalingam S, Urbanic J, et al. CheckMate 73L: a Phase 3 study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab with or without ipilimumab versus concurrent chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage III non-small-cell lung cancer. Clin Lung Cancer. 2022;23(3):e264–e268. doi:10.1016/j.cllc.2021.07.005
  • Hotta K, Nishio M, Saito H, et al. First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis. Int J Clin Oncol. 2021;26(6):1073–1082. doi:10.1007/s10147-021-01899-8
  • Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65. doi:10.1016/S1470-2045(20)30539-8
  • Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. doi:10.1001/jamaoncol.2018.3923
  • Lacouture M, Sibaud V. Toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19(Suppl 1):31–39. doi:10.1007/s40257-018-0384-3
  • Mathieu L, Shah S, Pai-Scherf L, et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist. 2021;26(5):433–438. doi:10.1002/onco.13752
  • Sugihara Y, Kawai T, Yamada D, Furuyama C, Sato Y, Kume H. Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: a report of two cases. Eur J Cancer. 2020;126:91–92. doi:10.1016/j.ejca.2019.12.009
  • Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301–1311. doi:10.1200/JCO.21.01308

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.